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Summary 
The proto-oncogene c-fos is a major nuclear target for 
signal transduction pathways involved in the regula- 
tion of cell growth, differentiation, and transformation. 
Using the multistep skin carcinogenesis model, we 
have directly tested the ability of c-los-deficient mice 
to develop cancer. Upon treatment with a tumor pro- 
moter, c-los knockout mice carrying a v-H-ras transgene 
were able to develop benign tumors with similar kinet- 
ics and relative incidence as wild-type animals. How- 
ever, c.fos-deficient papillomas quickly became very 
dry and hyperkeratinized, taking on an elongated, 
horny appearance. While wild-type papillomas eventu- 
ally progressed into malignant tumors, c-los-deficient 
tumors failed to undergo malignant conversion. Ex- 
periments in which v-H-ras-expressing keratinocytes 
were grafted onto nude mice suggest that c-los-defi- 
cient cells have an intrinsic defect that hinders tumor- 
igenesis. These results demonstrate that a member of 
the AP-1 family of transcription factors is required for 
the development of a malignant tumor. 
Introduction 
Advances in molecular biology have served to outline the 
multiple genetic components that are involved in the devel- 
opment of cancer. It is now well established that for a cell 
to grow aggressively within the context of the organism, 
proto-oncogenes must be mutated to become active 
growth inducers, tumor suppressor genes must be func- 
tionally lost, and the cell must be released from its own 
self-destruction program. Many of the important mole- 
cules in cancer development are proteins that function 
outside the nucleus of the cell, either assessing changes in 
the extracellular environment or relaying messages from 
sensor proteins to the control center of the cell. Because 
mitogens, growth factors, and tumor promoters regularly 
use these signal transduction pathways, mutations in 
genes implicated in either signal recognition or propaga- 
tion can induce the cell to behave inappropriately. Upon 
reaching the nucleus, signals from these proteins must 
communicate with transcription factors to elicit the changes 
in gene expression that can allow the cell to react to its 
new environment. 
One class of transcription factors that it is thought to 
serve as the nuclear target of m any oncogenic signal trans- 
duction pathways is the activator protein 1 (AP-1) family 
(reviewed by Ransone and Verma, 1990; Angel and Karin, 
1991). This multigene group includes members of the Fos 
(c-fos, fosB, fra- l , and fra-2) and Jun (c-jun, junB, and junD) 
families. Members of the Fos family form heterodimers 
with Jun proteins and regulate transcription by binding 
DNA at AP-1 sites. These cis-acting regulatory elements 
are found in a variety of genes involved in cell proliferation, 
differentiation, and tumorigenesis. Oncogenic activation 
of several signal transduction pathways can result in in- 
creased AP-1 activity. For example, tumorigenic muta- 
tions in the proto-oncogene H-ras activate a family of mito- 
gen-activated protein (MAP) kinases (JNKs/SAPKs) that 
phosphorylate Ju n to augment its transactivation potential 
(Pulverer et al., 1991; Binetruy et al., 1991). Recently, an 
analogous class of Ras-responsive intracellular kinases 
has been described that seems to regulate Fos activity 
(Deng and Karin, 1994). It is unclear from these in vitro 
studies, however, how elevated AP-l-dependent gene ex- 
pression can contribute to cancer development in vivo. 
A clue to the significance of AP-1 activity for cell transfor- 
mation can be found in the history of fos and jun, as both 
genes were initially described as the transforming princi- 
ples of oncogenic retroviruses (Curran et al., 1982; Maki 
et al., 1987). Later studies using transgenic mice showed 
that stable expression of c-fos led to a dysregulation of 
bone growth eventually resulting in osteosarcomas and 
chondrosarcomas (Ruther et al., 1987, 1989). Transgenic 
mice expressing an oncogenic form ofjun developed fibro- 
sarcomas at sites of wound healing (Schuh et al., 1990). 
These observations indicated that aberrant expression of 
AP-1 genes could affect mitogenic control and promote 
neoplastic transformation of specific tissues. 
Through the use of embryonic stem cell gene targeting 
technology, null mouse mutations of c-fos and c-jun have 
recently been generated (Johnson et al., 1992, 1993; 
Wang et al., 1992; Hilberg et al., 1993). While the c-jun 
knockout mutation is embryonic lethal, the c-fos null 
mouse is viable, though it displays a variety of tissue- 
specific anomalies. These defects include a severe form 
of osteopetrosis, a mild lymphopenia, delayed gameto- 
genesis, and some behavioral abnormalities. In spite of 
these deficiencies, the availability of these mutant mice 
has allowed us to use them as tools to study the role of 
c-fos in cancer development in vivo. Our intention was to 
examine the unfolding of the neoplastic process in the 
absence of a critical component of the AP-1 family. 
To address the relevance of c-fos for cancer develop- 
ment, we have used the classical model of multistep 
mouse skin carcinogenesis (reviewed by DiGiovanni, 
1992; Hennings et al., 1993; Yuspa, 1994). Tumor devel- 
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opment in mouse skin can be divided into three steps: 
initiation, promotion, and progression. Initiation is an irre- 
versible step that experimentally can be brought about 
by the application of a single dose of a mutagen (e.g., 
2,5-dimethoxybenzaldehyde [DMBA]). Initiated cells can 
lie dormant until they are induced to proliferate, either by 
repeated treatments with a tumor promoter (e.g., 12-0- 
tetradecanoylphorbol-13-acetate [TPA]) or by a natural 
promoting stimulus such as wounding. During promotion, 
initiated cells are thought to have a growth advantage, 
and the tissue hyperplasia eventually results in a visible 
benign clonal outgrowth, a papilloma. Over time, papillo- 
mas can accumulate additional genetic mutations and 
progress into a malignant umor, a squamous cell carci- 
noma. Carcinomas can undergo a further epithelial-mes- 
enchymal transition to give rise to highly invasive spindle 
cell tumors (Klein-Szanto et al., 1989; Buchmann et al., 
1991). 
In this study, we have found that while c-fos does not 
seem to be necessary for normal epidermal differentiation 
or for the early proliferative steps of skin tumor formation, 
it is required for malignant tumor conversion. These results 
offer clear genetic evidence that an AP-1 factor is indis- 
pensable for the development of certain cancers. 
Results 
c-fos-Deficient Keratinocytes Form 
a Normal Epidermis 
The skin is one of the few adult tissues in which c-fos 
expression has been reported to be constitutive (Fisher 
et al., 1991 ; Smeyne et al., 1992). Coupled with the obser- 
vation that functional AP-1 sites can be found in a variety 
of genes associated with epidermal development, his find- 
ing raised the possibility that the skin of c-fos null mice 
could display an aberrant pattern of differentiation. To un- 
cover any intrinsic abnormalities in unperturbed c-los- 
deficient skin, we stained newborn epidermis with markers 
for specific stages of keratinocyte differentiation. Figure 
1A shows double-labeled immunofluorescence staining 
for three markers: keratin 14 (K14), expressed in proliferat- 
ing basal keratinocytes; keratin 1 (K1), induced in the dif- 
ferentiating spinous cells; and Ioricrin, a component of the 
cornified envelope expressed in the terminally differenti- 
ated cells of the granular layer. Comparison of the staining 
patterns for these and other epidermal differentiation 
markers failed to reveal any differences among mice of 
varying c-los genotype. Histological examination of new- 
born c-los-deficient skin showed that no obvious differ- 
c-los(+/+) c-fos(-/-) Figure 1. Analysis of Wild-Type and c-los- 
Deficient Epidermis 
(A) Indirect immunofluorescence staining of 
epidermal differentiation markers in newborn 
epidermis. In the top panels, K14 staining is 
shown in green and K1 in red. Areas of overlap 
appear yellow. The bottom panels show K14 
in green and Ioricrin in red. Again, areas of 
common staining are yellow. Magnification, 
204 x. 
(B) Hematoxylin a d eosin staining of wild-type 
and c-fos-deficient newborn skin. Magnifica- 
tion, 163x. 
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ences exist in epidermal organization or cellularity (Figure 
1B). Analogous results were obtained with thinner adult 
skin. Furthermore, when newborn mice were injected with 
bromodeoxyuridine to identify epidermal cells undergoing 
DNA replication, the number of proliferating cells was 
found to be similar in both genotypes (data not shown). 
These observations allowed us to conclude that, on the 
basis of keratinocyte growth rate or pattern of differentia- 
tion-dependent gene expression, the skin of c-los-deficient 
mice is indistinguishable from that of wild-type mice. 
c-los Is Not Required for the Early Stages 
of Skin Carcinogenesis 
To induce tumor formation in the skin of mice, we used 
a modified version of a traditional DMBA/TPA tumor induc- 
tion protocol. Instead of using a chemical initiator, c-los 
mutant mice were bred with a transgenic strain (TG.AC) 
carrying a v-H-ras transgene that can act as a classical 
initiation event (Leder et al., 1990). The existence of this 
transgenic strain enabled us to avoid the use of initiators 
that would have introduced undefined genetic mutations, 
potentially complicating the interpretation of the results. 
Even though the transgene is under the control of an em- 
bryonic globin promoter and thus is not normally active 
in the skin, expression of the transgene is induced in epi- 
dermal cells when they are prompted to proliferate ither 
by application of tumor promoters or by a natural stimulus 
such as hair plucking (Hansen and Tennant, 1994a, 
1994b). Mice carrying the TG.AC transgene are very sensi- 
tive to a variety of tumor promoters; they rapidly develop 
large numbers of papillomas (Spalding et al., 1993). 
Mice homozygous for the TG.AC transgene were mated 
with mice heterozygous for the c-los null mutation. Off- 
spring carrying both mutations were identified and in- 
terbred to generate mice of all possible genotypes. The 
dorsal epidermis of these mice was then treated with the 
tumor promoter TPA twice a week for 5 weeks, according 
to standard promotion protocols for the TG.AC strain. 
Treated mice were monitored biweekly for the appearance 
of papillomas. As can be discerned from Figure 2, c-los- 
deficient mice were able to develop papillomas, and they 
did so with equivalent kinetics to those of their wild-type 
and heterozygous littermates. Furthermore, the time to 
appearance of the first tumor and the number of papillo- 
mas per mouse were indistinguishable among genotypes. 
Because papillomas are very heterogenous and often tend 
to coalesce with other papillomas, size comparisons are 
difficult. Nevertheless, no obvious differences in tumor 
size could be observed among mice of differing geno- 
types. 
Table 1 summarizes benign tumor incidence rates. A 
small minority of v-H-ras transgenic mice in each group 
proved to be resistant to TPA treatment. This resistance 
did not correlate with c-los genotype and has previously 
been described for inbred FvB/N TG.AC mice. Two conclu- 
sions can be drawn from the data in Table 1 regarding 
the role of c-los in the early steps of mouse skin carcino- 
genesis. First, the absence of c-los cannot act as an initiat- 
ing mutation because TPA-treated c-los null mice not car- 
rying the v-H-ras transgene did not develop papillomas. 
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Figure 2. Initial Kinetics of Papilloma Appearance 
Number of papilloma-bearing mice as a percentage of those treated 
with tumor promoter: wild-type mice (closed circles; n = 19), heterozy- 
gous mice (open squares; n = 35), and c-los null mice (open circles; 
n = 29). 
Second, since c-los-deficient mice bearing the v-H-ras 
transgene developed papillomas in a normal manner, it 
is clear that in this model of carcinogenesis, this proto- 
oncogene is not necessary for promotion. 
c-los-Deficient Papillomas Evolve into Horny, 
Elongated Tumors Characterized 
by Massive Hyperkeratinization 
Although c-los-deficient papillomas initially displayed an 
identical external appearance to wild-type tumors, a strik- 
ing change in morphology was noticed soon after the end 
of promotion. Within 4 weeks after TPA treatment was 
completed, the papillomas on all c-los null mice started 
to become very dry, elongated, and hyperkeratinized. This 
change in morphology was very apparent as the study 
advanced. Though some papilloma regression was ob- 
served in mice of all genotypes, the papillomas that per- 
sisted on wild-type and heterozygous mice remained vigor- 
ous and well vascularized. In contrast, mutant papillomas 
became desiccated and extremely hyperkeratinized and 
showed little external vascularization. Figure 3A shows a 
comparison of wild-type and c-los null papillomas soon 
after the end of promotion. While wild-type papillomas re- 
tained a similar morphology until the end of the study, 
c-los-deficient tumors acquired a rather horny appear- 
ance: they evolved into severely keratinized, grotesque 
projections. Examples of these older c-los-deficient tu- 
mors are shown in Figure 3C. Histopathology of wild-type 
and mutant papillomas revealed that c-los-deficient u- 
mors indeed display a very dramatic hyperkeratinization, 
showing a remarkable increase in the terminally differen- 
tiated stratum comeum (Figure 4). In addition, c-los- 
deficient papillomas eemed to present an abrupt transi- 
tion between the basal layer and the stratum corneum, 
possibly suggesting a contraction of either the stratum 
spinosum or the granular layer. Tumors heterozygous for 
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Table 1. Benign Tumor Incidence Rates 
Genotype Treatment Papillomas Incidence (%) Papillomas per Mouse Time to First Tumor 
c-fos wild-type transgenic v-H-ras TPA 17 of 19 90 
Acetone 0 of 4 0 
c-fos heterozygous transgenic v-H-ras TPA 30 of 35 86 
Acetone 0 of 5 0 
c.fos-deficient transgenic v-H-ras TPA 26 of 29 90 
Acetone 0 of 6 0 
c-fos wild type TPA 0 of 9 0 
c-fos heterozygous TPA 0 of 13 0 
c-fos deficient TPA 0 of 6 0 
26 ± 14.4 33.4 ± 7.2 
22 ± 15.7 34.8 -+ 8.9 
23 ± 14.3 32.0 ± 7.7 
At 12 weeks of age, all mice were shaved and promotion treatment was started either with TPA or with solvent alone (acetone). Mice were monitored 
biweekly for the appearance of tumors. Papillomas per mouse and time to first tumor statistics are given as mean ± SD. 
the c-fos null mutation appeared identical to wild-type pap- 
illomas: their morphology did not change, and they did 
not present an abnormal epidermal architecture. 
To investigate whether these hyperkeratinized c-fos- 
deficient umors showed an abnormal rate of regression, 
we compared the average number of papillomas per 
mouse at 9 weeks and at 23 weeks. Since TPA treatment 
was discontinued at the end of week 5, the majority of 
regressing papillomas hould have disappeared by week 
23. In wild-type mice, the mean number of papillomas per 
mouse decreased from 26 at week 9 to 10.5 at week 23 (a 
60% reduction). Heterozygous mice showed a very similar 
decline, from 22.1 tumors per mouse at week 9 to 8.9 at 
week 23 (a 60% decrease). The mean number of papillo- 
mas per mouse in c-fos-deficient animals decreased from 
23 at week 9 to 4.7 at week 23 (an 80% reduction). These 
data show that c-fos is not required for the persistence of 
papillomas. Whether papilloma regression rates are signif- 
icantly affected by the c-fos null mutation is an issue that 
will require more study. 
Papillomas Lacking c-fos Fail to Undergo 
Malignant Conversion 
Wild-type mice began to develop malignant skin tumors 
around week 20, although most cases of malignant pro- 
gression were noticed between weeks 25 and 30. Malig- 
nant lesions first appeared as ulcerated areas within a 
papilloma that grew rapidly. These malignant tumors were 
identified histologically as either squamous cell carcino- 
mas or, more frequently, spindle cell tumors, in agreement 
with what has been described for the TG.AC strain (French 
et al., 1994). By the end of the study (week 45), malignant 
progression had been observed in 4 of 7 (57%) surviving 
wild-type mice and in 7 of 17 (41%) heterozygous mice 
(Table 2). In contrast, no malignant skin tumors had been 
detected in 13 remaining c-fos null mice. A detailed patho- 
logical examination of all remaining c-fos-deficient papillo- 
mas at the end of the study failed to find any evidence of 
microscopic malignant progression. The decrease in the 
number of mice that were available at the later timepoint 
to assess progression is a reflection of the fact that the 
v-H-ras TG.AC transgene induces a variety of other tumors 
(e.g., hematopoietic malignancies) that necessitate the 
sacrifice of the affected animal. Nevertheless, the differ- 
ence in progression rates of tumors with or without c-fos 
(57% and 41% versus 0%) is statistically significant (p < 
0.0001) and allows us to conclude that c-fos is required 
for malignant progression of experimentally induced skin 
tumors. Wild-type and c-fos-deficient papillomas expressed 
similar levels of transgenic v-H-ras 1 month after the end 
of tumor promoter treatment (Figure 5B). Hence, the inabil- 
ity of c-fos-deficient papillomas to become malignant is 
not due to a reduced level of oncogenic H-ras expression. 
These final progression figures do not exclude the possibil- 
ity of a heterozygous effect, although the finding that het- 
erozygous papillomas behave like wild-type papillomas by 
all criteria examined argues against it. 
Alterations in Gene Expression 
in c-fos Null Papillomas 
To examine whether the lack of malignant progression of 
c-fos-deficient umors correlated with specific changes in 
gene expression, we isolated RNA from pools of papillo- 
mas from wild-type and c-fos-deficient mice. Each pool 
consisted of five to six tumors taken 1 month after the end 
of TPA treatment. These RNAs were used to measure the 
degree of expression of certain AP-l-regulated genes in 
the papillomas. The genes encoding the tumor metallopro- 
teases stromelysin and type I collagenase were of particu- 
lar interest because studies using c-fos-deficient fibro- 
blasts had shown that c-fos is required for the induction 
of these genes in response to mitogenic stimulation (Hu 
et al., 1994). In addition, enhanced expression of these 
tumor metalloproteases has been associated with the pro- 
gression of benign, encapsulated papillomas to malignant, 
invasive tumors (Matrisian et al., 1986; Liotta and Stetler- 
Stevenson, 1990). While the stromelysin and type I colla- 
genase mRNAs were detectable in the pools of wild-type 
tumors, they were virtually absent in RNA pools from 
c-fos-deficient papillomas (Figures 5A and 5B). The appar- 
ent lack of external vascularity of mutant tumors also 
prompted us to assess the level of expression of angio- 
genic factors in the papillomas. Of special interest was 
the pattern of expression of vascular endothelial growth 
c-fos and Malignant Progression 
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A 
(+/+) (-/-) 
8 weeks 
Figure 3. External Appearance of Papillomas 
(A) A wild-type mouse (left) and a c-fos-deficient littermate (right) are 
shown 3 weeks after the end of promotion. 
(B) c-fos null mouse 9 weeks after the end of promotion (14 weeks 
from the start of treatment); note the change in morphology that is 
now obvious in all papillomas. 
(C) Wild-type and c-fos-deficient umors 4 months after the conclusion 
of TPA treatment. The black mouse is the same mouse as that shown 
in (B). Notice the absence of external vascularity in the large tumors 
of the brown c-fos-deficient mouse. Color coat segregates indepen- 
dently of both the TG.AC transgene and the c-fos null mutation. 
"C 
(-/-) 
14- weeks 
(+I+) 
23 weeks 
(-/-) 
(-/-) 
factor (VEGF), for this protein may be the prime regulator 
of normal and tumor angiogenesis (Klagsbrun and Soker, 
1993). The VEGF gene was expressed in c-fos-deficient 
tumors, but the levels of VEGF mRNA measured in mutant 
papil lomas were 5- to 10-fold lower than those found in 
RNA pools derived from wild-type papil lomas (Figure 5C). 
The changes in keratin gene expression that take place 
during a protocol of skin carcinogenesis are well estab- 
lished and can often serve as markers of the degree of 
tumor progression. For example,  papil lomas with a high 
risk for malignant conversion frequently replace K1 ex- 
pression with that of K13, a keratin whose expression is 
normally restricted to internal epithelia (Nischt et al., 1988; 
Gimenez-Conti et al., 1990). Regions of premalignant pap- 
il lomas that express K13 do not normally express KI .  To 
monitor keratin gene expression in c-fos-deficient papillo- 
mas, we stained serial sections of tumors with antibodies 
prepared against an array of keratins. Surprisingly, K13 
expression was ubiquitous in the suprabasal layers of 
c-fos-deficient papil lomas. More significantly, though, 
while K1 and K13 expression was mutually exclusive in 
wild-type papil lomas, these two keratins were, invariably 
coexpressed in the same cells in the mutant papil lomas. 
K1 expression persisted in spite of K13 induction in all 
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c-fos(+/+) c-los(-/-) Figure 4. Histology of Papillomas 
Hematoxylin and eosin-stained sections of 
2-month-old tumors (3 weeks after TPA re- 
moval). The top panels show a wild-type and 
a c-fos-deficient umor at the same level of 
magnification (13 x). Note the striking hyper- 
keratinization of the fos-less papilloma nd the 
abrupt transition between the basal (b) and the 
cornified layers (sc). At higher magnification 
(135 x ; same for both genotypes), the contrac- 
tion of the layers in the c-fos-deficient umor 
becomes more evident. 
c-fos-deficient papil lomas examined (Figure 6). Since 
these type 1 and type 2 keratins do not normally form 
fi lament pairs, coexpression of K! and K13 in the same 
cells could result in the formation of an irregular intermedi- 
ate fi lament network that may contribute to the unusual 
amount of cornification displayed by mutant papillomas. 
In contrast with wild-type cornified envelopes, which disas- 
sociate when tumors are boiled, large clumps of tightly 
connected c-fos-deficient envelopes endured even after 
the mutant papil lomas were boiled for 5 hr in 2% SDS (data 
not shown). The considerable durability of c-fos-deficient 
cornified envelopes may reflect interesting underlying bio- 
chemical differences, such as covalent modifications in 
the structure of the envelopes. 
c-fos-Deficient Keratinocytes Expressing v-H-ras 
Do Not Form Tumors When Grafted 
onto Nude Mice 
The development of a malignant neoplasm is a process 
that involves an intense interaction between tumor cells 
and normal neighboring cells (reviewed by Paweletz and 
Boxberger, 1994). The inability of c-fos-deficient papillo- 
mas to progress into malignant tumors could be due to 
an intrinsic defect in the v-H-ras-expressing keratinocytes 
that form the epidermal component of the papil lomas. AI- 
Table 2. Incidence of Malignant Tumors 
Malignant Percent 
Genotype Tumors Affected 
c-fos wild-type transgenic v-H-ras 4 of 7 57 
c-fos heterozygous transgenic v-H-ras 7 of 17 41 
c-fos deficient transgenic v-H-ras 0 of 13 0 
Mice were monitored weekly during 45 weeks for the appearance of 
malignancies. At the end of that time, all mice were sacrificed, and any 
remaining tumors were harvested for pathological analysis. Individual 
mice were sacrificed after the first malignant umor was detected. 
ternatively, it is possible that malignant umors do not arise 
in these animals because the nontransformed c-fos- 
deficient cells neighboring the neoplastic keratinocytes do 
not provide an environment hat is conducive for malignant 
papillomas 
A (+/4") ('/') 
stromelysin 
36B4 
B (+/+) ('/-) 
type I 
collagenase 
v-H-ras 
36B4 
C (+/+) ('/') 
VEGF 
36B4 ~ ~ ~ 
Figure 5. Expression of c.fos-Regulated Genes in Papillomas 
RNA was prepared from papillomas 1 month after the end of promotion 
and analyzed by Northern blot. Each lane contains total RNA from a 
pool of six to eight tumors. Probes are as indicated on each panel. 
Blots were stripped and reprobed with ribosomal-associated protein 
36B4 as a control for loading. 
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c-fos(+/+) 
K13 
c-fos(-/-) Figure 6. Aberrant Keratin Gene Expression 
in c-fos-Deficient Papillomas 
Serial sections of tumors (obtainecl 2.5 months 
after the start of the study) were stained with 
antibodies against K1 (bottom) and K13 (top) 
and photographed at the same magnification 
(32x). Note the coexpression of K1 and K13 
in c-fos-deficient umors. 
K1 
growth. To establish whether c-fos-deficient keratinocytes 
display a cell-autonomous defect that prevents them from 
giving rise to malignant tumors, we tested the ability of 
v-H-ras-expressing mutant keratinocytes to form tumors 
when grafted onto the back of wild-type hosts (Hoop et al., 
1986). Primary keratinocytes derived from c-fos-deficient, 
heterozygous, and wild-type mice were infected with a 
helper-free retrovirus, a variant Harvey murine sarcoma 
virus (Ha-MSV), expressing an oncogenic form of H-ras 
(Hoop et al., 1986), were mixed with wild-type dermal fibro- 
blasts, and were grafted onto the back of athymic nude 
mice. Grafted Ha-MSV-infected wild-type keratinocytes 
gave rise to large papillomas. In contrast, grafts of infected 
c-fos-deficient keratinocytes did not produce significant 
tumors. Rather, v-H-ras-expressing cells lacking c-fos gen- 
erated a normal epidermis that was hyperplastic in some 
cases. Interestingly, grafts of keratinocytes heterozygous 
for the c-fos null mutation gave rise to small tumors of 
variable size that on average were approximately 35% the 
size of their wild-type counterparts. While there was some 
variation in absolute tumor volume values, the same trend 
was observed in three independent experiments: v-H-ras- 
expressing keratinocytes homozygous for the c-fos null 
mutation failed to produce tumors (n = 8), heterozygous 
cells generated small, fragmented papillomas (n = 12), 
and wild-type keratinocytes gave rise to large tumors 
(n = 14). Mice from a representative experiment are 
shown in Figure 7A. The presence of black pigment in 
mice with grafts of c.fos-deficient keratinocytes indicates 
that the graft was successful. Figure 7B displays the evolu- 
tion of tumor volume as a function of time for that same 
experiment. Mice with c-fos-deficient grafts failed to de- 
velop tumors, even when monitored for 3 months (6 weeks 
beyond the normal observation period). Since tumor for- 
mation in this system is dependent upon oncogenic H-ras 
expression, the levels of mutant Has protein in keratino- 
cytes used for grafting were examined. All Ha-MSV- 
infected keratinocytes, regardless of genotype, expressed 
equivalent levels of exogenous Has in vitro as well as in 
vivo (data not shown). The growth rate in vitro of all v-H-ras- 
expressing keratinocytes was similar, regardless of c-fos 
genotype (data not shown). Furthermore, implanted c-fos 
null keratinocytes coinfected with Ha-MSV and a v-fos ret- 
rovirus generated dysplastic tumors indistinguishable 
from those produced by similarly infected wild-type cells, 
confirming that a fos-dependent function is responsible 
for the deficiency in tumor formation of mutant cells (data 
not shown). These transplantation experiments illustrate 
that v-H-ras-expressing keratinocytes derived from c-fos 
null animals appear to have a cell-autonomous defect that 
hampers tumorigenesis. 
Discussion 
Tumorigenesis is a complex process that requires alter- 
ations in many genes involved in the regulation of cell 
growth. Many of these genes function outside of the nu- 
cleus of the cell and must ultimately exert their effects by 
communicating with transcription factors. The AP-1 family 
is believed to be one of the nuclear targets of several signal 
transduction pathways, in particular the Has-MAP kinase 
pathway (reviewed by Hill and Treisman, 1995). Because 
these pathways are frequently dysregulated by activated 
oncogenes, it is of considerable interest to determine 
whether AP-1 factors are actually necessary for cancer 
development. We have used the well-characterized model 
of multistep mouse skin carcinogenesis to examine the 
unfolding of the neoplastic process in the absence of c-fos, 
an important member of the AP-1 family. Our results dem- 
onstrate that c-fos is required for the development of malig- 
nant skin tumors. 
The Role of c-fos in Initiation and in Promotion 
To test the role of c-los in the various steps of skin carcino- 
genesis, we mated mice heterozygous for the c-fos null mu- 
tation with a transgenic strain carrying a v-H-ras transgene 
A 
B 
2000. 
Cell 
728 
c-fos (+/+) c. fos (./-) 
Figure 7. Graftingofv-H-ras-ExpressingKera- 
tinocytes 
(A) Appearance of grafts of Ha-MSV-infected 
keratinocytes 6 weeks after implantation. The 
genotype of grafted keratinocytes is shown be- 
low each picture. The presence of pigment (de- 
noting cells of the C57BL/6J x 129/SVJ ge- 
netic background) indicates that grafts were 
successful. 
(B) Tumor development as a function of time 
for grafts of wild-type (n = 4), heterozygous 
(n = 5), and c-fos-deficient (n = 3) v-H-ras. 
expressing keratinocytes. Curves represent 
the average tumor volume for each group. Er- 
ror bars denote SEM. Note that c-fos-deficient 
cells did not give rise to tumors. 
1500. 
~, 1000- 
500- 
k 
1 2 3 4 5 6 
Weeks after grafting 
c-fos +/+ 
+ c-fos +/- 
c-fos 4- 
that can substitute for a chemical initiation step. Even 
though mutations in H-ras are very common during initia- 
tion in DMBA/TPA protocols, skin tumors induced with 
other carcinogens frequently do not bear H-ras mutations 
(Bremner et al., 1994). This observation suggests that mu- 
tations in other unspecified genes can also serve as initiat- 
ing events. To examine whether c-fos could be one of 
these unidentified genes, we treated c-fos null mice not 
carrying the v-H-ras transgene with the tumor promoter 
TPA. The absence of papilloma formation established that 
a c-fos null mutation cannot serve as an initiation event. 
Mutant mice bearing the v-H-ras transgene were able 
to develop papillomas normally upon TPA treatment. That 
c-fos-deficient papillomas appeared with standard kinetics 
and in comparable numbers to wild-type tumors shows 
that, under these experimental conditions, c-fos is not re- 
quired for benign tumor formation. Because c-fos is an 
immediate-early gene whose expression is often used as 
a marker of cellular proliferation, itmay have been antici- 
pated that the main contribution of c-fos to oncogenesis 
would be either to accelerate the rate of cell division or 
to prevent exit from the cell cycle. Clearly, this does not 
seem to be the case in this study. It is possible that during 
promotion, TPA induces the expression of other genes 
that can functionally complement he absence of c-fos. 
Nonetheless, since in the vast majority of experimental 
carcinogenesis protocols, TPA promotion is continued for 
many weeks, the real relevance, if any, of c-fos for tumor 
promotion would also be concealed under those circum- 
stances. Thus, we can conclude that, while it may be im- 
portant, c-fos is not essential for tumor promotion brought 
about by TPA treatment. 
Abnormalities of Epidermal Differentiation 
in c-fos-Deficient Papillomas 
Although initially identical to wild-type papillomas, shortly 
after the end of TPA treatment, c-los-deficient umors be- 
gan to manifest some clear differences. Over time, c-fos- 
deficient papillomas are characterized by a grotesque hy- 
perkeratinization. Mutant papillomas evolve into horny 
projections covered by a crust of keratin that can grow 
as long as 2-3 cm. The development of such elongated, 
hyperkeratinized papillomas (with the great frequency 
found here) seems to be unique for a carcinogenesis proto- 
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col. It was surprising to find universal K13 expression in 
these apparently benign tumors, for K13 induction has 
heretofore been considered a useful diagnostic of prema- 
lignant progression. It is important o note that these c-fos- 
mediated differences in epidermal differentiation are only 
apparent within the context of carcinogenesis, for no differ- 
entiation abnormalities were detected in untreated c-fos- 
deficient epidermis. Hence, it is conceivable that the ob- 
served differences are contingent on the expression of a 
mutant H-Ras protein. It is also possible that the expres- 
sion of the various members of the AP-1 family may be 
abnormally regulated during tumorigenesis. Given the 
large number of AP-1 sites that have been identified in 
epidermal differentiation genes, disorderly expression of 
other AP-1 members in the absence of c-fos may have 
profound effects. Using immunohistochemistry, we have 
been unable to recognize significant differences in the 
expression pattern of AP-1 genes in wild-type and mutant 
papillomas (data not shown). However, since the activity 
of AP-1 proteins can be regulated by reversible phosphor- 
ylation, it is possible that differences may exist in AP-1- 
dependent gene expression that are not reflected in an 
unusual pattern of AP-1 family protein expression. 
The Role of c-los in Papilloma Survival 
and Malignant Progression 
In contrast with wild-type and heterozygous tumors, not a 
single c-fos-deficient papilloma progressed to malignancy 
by the end of the study. Several explanations can poten- 
tially account for this observation. It is well established 
that c-fos controls the expression of a variety of genes that 
are up-regulated during malignant progression, including 
those encoding the tumor metalloproteases tromelysin 
and type I collagenase (Kerr et al., 1988; Schonthal et al., 
1988; Hennigan et al., 1994). The tumor metalloproteases 
are a group of secreted enzymes that can degrade the 
extracellular matrix, thereby facilitating tumor growth, in- 
vasion, and metastasis (reviewed by Liotta and Stetler- 
Stevenson, 1990). Increased metalloprotease xpression 
has been associated with malignant progression in many 
models of in vivo cancer development (reviewed by 
McDonnell and Matrisian, 1990). Given that the transcripts 
for stromelysin and type I collagenase were undetectable 
in RNA obtained from pools of mutant papillomas, it is 
likely that a protease insufficiency may contribute to the 
lack of malignant behavior of c-fos-deficient umors. 
The sparse external vascularity displayed by c-fos- 
deficient papillomas suggests a second possible factor for 
the benign nature of c-fos-deficient tumors. At a molecular 
level, the formation of new blood vessels is a process re- 
markably similar to tumor invasion and metastasis, for an- 
giogenesis also requires cells to traverse normal tissue 
boundaries and degrade the basement membrane of the 
tissue to be vascularized (reviewed by Liotta et al., 1991). 
c-fos could be mediating tumor angiogenesis not only 
through its control of the proteases that are critical for 
these processes, but also by modulating the expression 
of the growth factors that induce neovascularization, such 
as VEGF. Indeed, we have observed that the level of VEGF 
mRNA is significantly reduced in RNA extracted from 
pools of c-fos-deficient umors. Finally, it is conceivable 
that the abnormal pattern of differentiation of c-fos- 
deficient papillomas may interfere or be incompatible with 
ordinary tumor progression. 
Diminished expression of tumor metalloproteases and 
angiogenic factors may also contribute to the inability of 
grafted v-H-ras-expressing c-fos-deficient keratinocytes to 
generate papillomas. The development of an established 
graft/tumor involves complex fibroblast-keratinocyte in- 
teractions that must ultimately result in, among other 
things, the creation of a new blood vessel network to sup- 
port the growth of the graft (Smola et al., 1993; Borchers 
et al., 1994). In the multistep carcinogenesis ystem, the 
requirement for angiogenesis may be less stringent, at 
least for the early stages of tumor development. Since 
tumors are induced in skin that is already vascularized, 
initially neoplastic cells need only to expand the existing 
capillary network, not to establish a completely new one. 
It is also possible that chemical treatment in the multistep 
carcinogenesis system induces the expression of genes 
that allow papilloma formation in the absence of c-fos. 
Many genes, including those encoding the tumor metallo- 
proteases stromelysin and type I collagenase, are known 
to be expressed in response to tumor promoter stimula- 
tion; c-fos-deficient fibroblasts can express a limited 
amount of these proteases when stimulated with TPA 
(Krieg et al., 1988; Hu et al., 1994). The defect in tumor 
development observed in the grafting system could also be 
due to an autocrine overproduction of a growth-inhibiting 
molecule (e.g., transforming growth factor 13) by c-fos- 
deficient cells. Alternatively, v-H-ras-expressing mutant 
cells may be more sensitive to constraining signals ema- 
nating from the wild-type cells that constitute the stromal 
component cf the implant. The experimental flexibility of 
the skin grafting system should permit the reintroduction 
of proteases and angiogenic factors to test whether the 
cell-autonomous defect in tumorigenesis of c-fcs-deficient 
keratinocytes is linked to the expression of these genes. 
Although the specific details of why c-fos-deficient papil- 
lomas fail to progress to malignancy are yet to be eluci- 
dated, these findings might provide a molecular mecha- 
nism for the observation that treatment with retinoids and 
glucocorticoids can prevent malignant progression of 
mouse skin tumors, as well as the occurrence of second- 
ary tumors in carcinomas of the head and neck in humans 
(Hong et al., 1990; Strawhecker and Pelling, 1992; De 
Luca et al., 1993). Both, the retinoic acid receptors and 
the glucocorticoid receptor are known to antagonize AP-1- 
dependent ranscription directly (Schule et al., 1990; Kerp- 
pola et al., 1993). Thus, it is possible that the inhibitory 
action of these hormones on AP-1 activity is at least par- 
tially responsible for their antitumorigenic effects. 
Relevance to Other Neoplastic Processes 
An important question is whether these findings will be 
meaningful for tissues other than the epidermis. We have 
indirectly addressed this issue by monitoring the fre- 
quency of the spontaneous tumors induced by the v-H-ras 
TG.AC transgene in c-fos-deficient mice. We have found 
that while c-fos is dispensable for the genesis of some 
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nonsol id  neop lasms,  it appears  to be crit ical for the devel-  
opment  of certa in sol id tumors,  such as odontogen ic  f ibro- 
sarcomas  (unpubl i shed data). Moreover ,  a var iety of other  
human and rodent  tumors  are  known to overexpress  c-fos 
(e.g., Honok i  et al., 1992; Urabe  et al., 1992). One of these 
tumors  is human squamous  cell carc inoma of the lung 
(Volm et al., 1992; Wodr ich and Volm, 1993). Because  the 
deve lopment  of  this cancer  natural ly requi res  repeated 
appl icat ions of a tumor  promoter  (e.g., tobacco  smoke) ,  
many cons ider  this human cancer  the most  accurate re- 
f lect ion of the mouse  skin model.  Another  cl inical ly rele- 
vant  tumor  in which c-fos overexpress ion  is assoc iated 
with' mal ignant  progress ion is human breast  cancer  (Bi- 
unno et al., 1988; Walker  and Cowl, 1991). 
Our  f indings highl ight the s igni f icance of  c-fos for full 
neoplast ic  deve lopment .  S ince mal ignant  progress ion is 
the most critical step in terms of  host survival,  the identifi- 
cat ion of agene  central  to this process  represents  a prom- 
ising step toward the therapeut ic  prevent ion of  neoplast ic  
d isease.  Furthermore,  because  c-fos is not required for 
the viabil ity of  the whole  organism,  it may represent  an 
attract ive target  for pharmaco log ica l  intervent ion.  
Experimental Procedures 
Animals 
c.fos-deficient mice were generated as previously described (Johnson 
et al., 1992). Mice heterozygous for the c-fos null mutation (50% 129/ 
SvJ; 50% C57BU6J) were mated with FvB/N mice homozygous for the 
TG.AC transgene obtained from Charles River Laboratories. Offspring 
carrying both the TG.AC transgene and the c-fos mutation were identi- 
fied and interbred. Their progeny was typed for both mutations and 
divided into the groups shown in Table 1. At 12 weeks of age, mice 
were shaved, and their dorsal epidermis was treated with either 5 ~g 
of TPA (Sigma) dissolved in 100 pJ of acetone or acetone alone. To 
normalize for their reduced size (and hence smaller dorsal surface 
area), c-fos-deficient mice received 55% of the wild-type dose of pro- 
moter. This dose of TPA resulted in a similar papilloma yield in wild-type 
and mutant mice (see Table 1). Treatment was applied twice a week for 
5 weeks. Male mice were caged individually to prevent wound-induced 
tumors. All mice were examined at least once a week for a period of 
45 weeks. 
Histology and Immunohistochemistry 
For pathological analysis, complete autopsies were performed and 
tissues were fixed in Optifix. Tumors were not removed from mice 
under observation. For fluorescent immunohistochemistry, neonatal 
skin was frozen in OCT (Miles Incorporated). Double-labeled indirect 
immunofluorescence was performed as described by Nischt et al. 
(1988). Antisera against mouse keratins and Ioricrin are characterized 
by Yuspa et al. (1989) and Mehrel et al. (1990). 
Cell Culture and Retroviral Infections 
Breeding pairs of animals heterozygous for the c-fos null mutation 
were monitored daily for the appearance of offspring. Neonatal mice 
were genotyped by PCR (Johnson et al., 1992). After sacrifice, animals 
were kept on ice until typing results became available (24 hr). The 
skin from selected mice was removed, and primary keratinocytes were 
prepared as described by Hennings et al. (1980). Dermal fibroblasts 
from the same c-los wild-type mice used to derive keratinocytes to be 
grafted were cultured separately for 1 week (Yuspa et al., 1976). Pri- 
mary keratinocytes were infected 3 days after plating at a multiplicity 
of 1 with a replication-defective variant of Ha-MSV devoid of helper 
virus and containing the v-H-ras gene (Roop et al., 1986). After 5 days, 
keratinocytes and fibroblasts were combined and grafted. Wild-type 
fibroblasts were used for grafting keratinocytes of all three genotypes. 
Successful Ha-MSV infection and p21 H,Ras expression were moni- 
tored by analyzing total protein extracts of infected keratinocytes by 
Western blot and by immunohistochemistry on grafts, using an anti- 
body against p21 H-Ras (Transduction Laboratories). 
In Vivo Grafting 
Combined cell pellets were transplanted onto 8- to 12-week-old 
athymic nude mice as described by Strickland et al. (1993). The volume 
of tumors was measured on a weekly basis, starting 2 weeks after 
grafting. Mice were sacrificed after 6 weeks of observation, unless 
otherwise noted. 
Statistical Analysis 
Statistical work was performed by the Division of Biostatistics at the 
Dana-Farber Cancer Institute. The associations between c-los geno- 
type and the incidence of epidermal tumors were analyzed with log 
linear models using GLIM (GLIM4, 1992 Royal Statistical Society, Lon- 
don), evaluating the association both assuming and not assuming and 
ordering to the genotype (+/+ > +/ -  > - / -) ;  p values of <0.05 were 
considered significant. 
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